Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma.

被引：0
|
作者：
Eroglu, Zeynep
Kim, Dae Won
Johnson, Douglas Buckner
Algazi, Alain Patrick
Munhoz, Rodrigo Ramella
Liniker, Elizabeth
Kong, Ben
Khurana, Neharika
Chmielowski, Bartosz
Sosman, Jeffrey Alan
Scolyer, Richard A.
Carlino, Matteo S.
Postow, Michael Andrew
Hwu, Wen-Jen
Long, Georgina V.
Ribas, Antoni
机构：
[1] City Hope Natl Med Ctr, Pasadena, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Vanderbilt Univ, Nashville, TN 37235 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] Melanoma Inst Australia, Sydney, NSW, Australia
[7] Westmead Canc Ctr, Strathfield, NSW, Australia
[8] UC San Francisco, San Francisco, CA USA
[9] Univ Calif Los Angeles, Los Angeles, CA USA
[10] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[11] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp, Sydney, NSW 2006, Australia
[12] Westmead Hosp, Baulkham Hills, Australia
[13] Melanoma Inst Australia, Sydney, NSW, Australia
[14] Univ Sydney, Sydney, NSW, Australia
[15] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9011
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Mechanisms of response to anti-PD1 (PD1) combined with Ipilimumab (IPI) in patients (pts) with PD1-resistant metastatic melanoma (MM)
    da Silva, Ines Pires
    Conway, Jordan
    Edwards, Jarem
    Marsh-Wakefield, Felix
    Quek, Camelia
    Ferguson, Angela
    Johnansson, Peter
    Carlino, Matteo
    Menzies, Alexander
    Wilmott, James
    Palendira, Umaimainthan
    Scolyer, Richard
    Long, Georgina
    CANCER RESEARCH, 2024, 84 (06)
  • [42] Intralesional anti-PD1 treatment in patients with metastatic melanoma: The pilot study.
    Samoylenko, Igor
    Korotkova, Olga V.
    Zabotina, Tatiana
    Demidov, Lev V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [43] Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies
    Cona, M. S.
    Lecchi, M.
    Damian, S.
    Del Vecchio, M.
    Cimminiello, C.
    Cresta, S.
    Duca, M.
    Necchi, A.
    Signorelli, D.
    Poggi, M.
    Raggi, D.
    Ratta, R.
    Verderio, P.
    de Braud, F. G. M.
    Di Nicola, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 35 - 35
  • [44] Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.
    Zimmer, Lisa
    Dimitriou, Florentia
    Grover, Piyush
    Hassel, Jessica Cecile
    Erdmann, Michael
    Forschner, Andrea
    Johnson, Douglas Buckner
    Livingstone, Elisabeth
    Roesch, Alexander
    Ugurel, Selma
    Schulz, Carsten
    Berking, Carola
    Menzies, Alexander M.
    Long, Georgina V.
    Dummer, Reinhard
    Schadendorf, Dirk
    Albrecht, Lea Jessica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
    Sun, Yiting
    Jiang, Liqing
    Wen, Ti
    Guo, Xiaoyu
    Shao, Xinye
    Qu, Hui
    Chen, Xi
    Song, Yujia
    Wang, Fang
    Qu, Xiujuan
    Li, Zhi
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [46] Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma
    Su, Chung-Wei
    Hou, Ming-Mo
    Huang, Pei-Wei
    Chou, Yung-Chih
    Huang, Bing-Shen
    Tseng, Jeng-Hwei
    Hsu, Chao-Wei
    Chang, Tung-Chieh
    Lin, Shi-Ming
    Lin, Chen-Chun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (04): : 1606 - +
  • [47] Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials
    Reuss, Joshua E.
    Stern, Diana
    Foster, Jared C.
    Ramaswami, Ramya
    Lurain, Kathryn
    Chen, Helen X.
    Streicher, Howard
    Kem, Ravie
    Little, Richard F.
    Sharon, Elad
    JAMA NETWORK OPEN, 2020, 3 (12) : E2027110
  • [48] Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis
    Liu, Yanhao
    Xu, Yan
    Cheng, Xi
    Lin, Yaru
    Jiang, Shu
    Yu, Haiming
    Zhang, Zhen
    Lu, Linlin
    Zhang, Xiaotao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [49] Purple papules during anti-PD1 immunotherapy for metastatic melanoma
    De Luca, Erika V.
    Catapano, Silvia
    Del Regno, Laura
    Di Stefani, Alessandro
    Peris, Ketty
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 (04): : 630 - 632
  • [50] Anti-PD1 therapy and CD8 T cell invigoration in metastatic melanoma
    Huang, Alexander
    Xu, Wei
    Harmon, Shannon
    Quagliarello, Felix
    Herati, Ramin
    Pauken, Kristen
    Bengsch, Bertram
    Schuchter, Lynn
    Amaravadi, Ravi
    McGettigan, Suzanne
    Gangadhar, Tara
    Wherry, John
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
12345